Breaking News
Subscribe Now 0
Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 place See list
Close

Celltrion Inc (068270)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
196,300 +2000    +1.03%
13:16:06 - Closed. Currency in KRW ( Disclaimer )
  • Volume: 158,847
  • Bid/Ask: 196,200 / 196,300
  • Day's Range: 194,200 - 196,800
Type:  Equity
Market:  South Korea
ISIN:  KR7068270008 
Celltrion 196,300 +2000 +1.03%

Celltrion Inc Company Profile

 
Get an in-depth profile of Celltrion Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

2034

Equity Type

ORD

Celltrion, Inc., together with its subsidiaries, develops and produces drugs based on proteins for the treatment of oncology in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; and covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 that is in phase 3 clinical trial for the treatment of asthma and urticaria; CT-P41, which is in phase 3 clinical trial for the treatment of osteoporosis and bone loss; CT-P42, which is in phase 3 clinical trial for the treatment of diabetic macular edema; and CT-P43 that is in phase 3 clinical trial for the treatment of psoriasis, crohn's disease, and ulcerative colitis. The company also offers CT-P47, which is in phase 3 clinical trial for the treatment of rheumatoid arthritis; and CT-P53 that is is in phase 3 clinical trial for the treatment of multiple sclerosis. Celltrion, Inc. was founded in 2002 and is headquartered in Incheon, South Korea.

Contact Information

Address 23 Academy-ro Yeonsu-gu
Incheon,
South Korea
Phone 82 3 2850 5000
Fax -

Top Executives

Name Age Since Title
Jung-Jin Seo 67 2002 Inside Co-Chairman of the Board
Byoung Hoon Jeon 67 2014 Independent Outside Director
Hyong-Gi Kim 59 2014 CEO & Internal Director
Woo-Sung Kee 63 2014 CEO & Internal Director
Jong Suk Lee 72 2014 Independent Outside Director
Jin-seok Seo - 2021 Co-CEO & Inside Co-Chairman of the Board
Byung-oh Kwon - - Director
Young-hyeh Ko - 2022 Independent Director
Keun-young Kim - 2022 Independent Director
Dae-hyun Yoo - 2022 Independent Director
Jae-sik Lee - 2022 Independent Director
Soon-Woo Lee 74 2022 Independent Director
Wonkyung Choi - 2023 Independent Director
Jongmoon Choi - 2023 Independent Director
Joong Jae Lee - 2023 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

068270 Comments

Write your thoughts about Celltrion Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email